Drug-Induced Liver Injury (DILI) - Management According to Sleisenger and Fordtran's Gastrointestinal and Liver Disease

1. Core Principle: Prevention Over Treatment

• Prevention and early detection
• Prompt withdrawal of the offending agent
• Safe use of OTC agents (acetaminophen, NSAIDs, complementary and alternative medicine [CAM] preparations)

2. Prevention Strategies

A. Idiosyncratic Hepatotoxins

• Avoid overuse - e.g., amoxicillin-clavulanic acid, flucloxacillin
• Avoid polypharmacy when possible
• Post-marketing surveillance and adverse effect reporting to monitoring agencies is mandatory

B. Dose-Dependent Hepatotoxins

• Adhere to dosage guidelines or monitor blood levels
• This approach has virtually abolished certain forms of DILI:
  • Tetracycline-induced fatty liver
  • Aspirin hepatitis
  • Methotrexate-induced hepatic fibrosis
• Specific contraindications:
  • Avoid valproic acid with other drugs in children < 3 years
  • Avoid methotrexate in excess alcohol consumers
  • Moderate acetaminophen doses are contraindicated in heavy drinkers and after prolonged fasting
  • Halothane should NOT be readministered within 28 days or in patients with suspected prior sensitivity to a haloalkane anesthetic

3. Early Detection

• Warn patients to report: unexplained nausea, malaise, right hypochondrial pain, lethargy, or fever - these may represent the prodrome of drug-induced hepatitis
• These symptoms are an indication for liver biochemical testing
• If liver tests suggest injury - stop the drug

Protocol Screening Recommendations:

• Routine (protocol) screening is NOT generally recommended, as:
  • Liver injury onset can be rapid, making monthly screening futile
  • Up to 7.5% of placebo-treated patients have persistently raised ALT
• Exceptions where protocol screening IS recommended:
  • Methotrexate (with biopsy/noninvasive fibrosis assessment)
  • Valproic acid, isoniazid, pyrazinamide, ketoconazole, dantrolene, thiazolidinediones, synthetic retinoids

Threshold for Stopping a Drug (using isoniazid as the model):

• Stop if serum ALT > 250 U/L or > 5x ULN
• Clearer indications to stop: elevated serum bilirubin, decreased albumin, prolonged prothrombin time, or any pertinent symptoms
• Note: Rise in serum GGTP or minor elevation of alkaline phosphatase usually indicates hepatic adaptation, not injury

4. General Management of Established DILI

"Failure to discontinue the offending drug is the single most important factor leading to poor outcomes, such as ALF and chronic liver disease."

• Aspiration of stomach contents (metals, acetaminophen)
• Methods to remove absorbed toxins: charcoal hemoperfusion, hemodialysis (limited efficacy)

• NAC (N-acetylcysteine): Can be used in acute liver failure (ALF) from DILI (not just acetaminophen)
• UDCA (ursodeoxycholic acid): May help in managing drug-induced cholestasis
• Glucocorticoids: Generally ineffective in drug-induced liver disease
  • Reserved for atypical/refractory cases - occasional effectiveness reported with etretinate, allopurinol, diclofenac, or ketoconazole
  • Should be reserved especially for cases associated with vasculitis
• Early referral for liver transplantation in ALF

5. Specific Management - Acetaminophen (Paracetamol) Hepatotoxicity

Initial Steps:

Risk Assessment:

• Measure serum acetaminophen levels (wait until >4 hours post-ingestion for reliable interpretation)
• Use the Rumack-Matthew nomogram (blood level vs. time after ingestion) to estimate hepatotoxicity risk
• Indications for antidote therapy:
  • Reliable history of major poisoning (>10 g)
  • Blood levels in moderate- or high-risk bands on nomogram

Antidote - N-Acetylcysteine (NAC):

• IV route: higher rate of hypersensitivity reactions (rash, angioedema, shock) - must be administered under close supervision
• In NAC-sensitized patients: methionine is an alternative (not commercially available; causes vomiting)
• Timing is critical: outcomes worsen with presentation > 16 hours after ingestion

Prognosis / LT Criteria:

• Assess candidacy for LT in established severe hepatic injury
• King's College Criteria are used (pH < 7.30 regardless of grade of encephalopathy; or PT > 100s + creatinine > 300 µmol/L + grade III-IV encephalopathy)

6. Valproic Acid - Specific Management

• Treatment is supportive
• IV L-carnitine supplementation can reduce hyperammonemia and improve survival in severe cases (small nonrandomized studies)
  • Also useful for hyperammonemic encephalopathy without overt liver disease (psychiatric patients)
• LT has been performed but poor outcomes reported in children; may be good in selected adults
• Prevention: Avoid in children < 3 years with polypharmacy; screen high-risk groups for POLG mutations

Summary Table

Hepamerz (LOLA) in Renal Failure

What is Hepamerz?

1. Stimulating the urea cycle in periportal hepatocytes (ornithine activates carbamoyl phosphate synthetase and ornithine transcarbamylase)
2. Stimulating glutamine synthesis in perivenous hepatocytes and skeletal muscle - providing an alternative route for ammonia detoxification
3. Net result: reduction in blood ammonia levels

Renal Failure - Official Contraindication

Absolute Contraindication: Severely impaired renal function (renal failure). A serum creatinine level in excess of 3 mg/100 ml (3 mg/dL) can be taken as a guide.

• Hepa-Merz Infusion concentrate (IV, 5g LOLA per 10ml ampoule)
• Hepa-Merz Granules/Sachets (oral, 3g LOLA per sachet)

Why is LOLA Contraindicated in Renal Failure?

Practical Guide by Renal Function

Clinical Scenario: HE + Renal Failure - What to Use Instead?

• Lactulose (first-line; renally safe - acts in the gut)
• Rifaximin (minimally absorbed; safe in renal failure - preferred add-on)
• Dietary protein management (adequate protein, prefer branched-chain amino acids)
• Zinc supplementation (supports urea cycle enzymes)
• Treat the precipitant - infection, GI bleed, overdiuresis, electrolyte disturbance

Note: In patients with hepatorenal syndrome (HRS), treating the underlying renal dysfunction (terlipressin + albumin for HRS type 1) can improve renal function enough to make LOLA use feasible later.

Evidence for LOLA in HE (for context)

Key Takeaway

Serum creatinine > 3 mg/dL = absolute contraindication to Hepamerz (both IV and oral). The mechanism is accumulation of aspartate and ornithine metabolites due to impaired renal clearance. In patients with HE and concurrent renal failure, lactulose + rifaximin remain the safe ammonia-lowering backbone.

Treatment of Erectile Dysfunction (ED)

Treatment Algorithm

Physiology Basis of Treatment

Step 1 - Identify and Treat Reversible Causes

• Antidepressants: SSRIs, TCAs, MAOIs
• Antihypertensives: beta-blockers, verapamil, clonidine
• Diuretics: thiazides, spironolactone
• Hormonal: corticosteroids, antiandrogens, 5α-reductase inhibitors, GnRH agonists/antagonists
• Cardiac: amiodarone, digoxin
• H2 blockers: cimetidine, ranitidine

Step 2 - Lifestyle Modification

• Weight reduction (obesity is a major modifiable risk factor)
• Exercise - improving cardiovascular fitness directly improves erectile function
• Smoking cessation
• Reduce alcohol consumption
• Patient and partner education and counseling

First-Line Treatment: Oral PDE5 Inhibitors

Mechanism

Available agents (Goodman & Gilman's):

• Overall efficacy: ~60% of men respond
• Response rates are somewhat lower in diabetes, spinal cord injury, post-prostatectomy, and pelvic irradiation
• Daily tadalafil 5 mg (start at 2.5 mg): preferred when intercourse expected >2x/week; also beneficial for LUTS/BPH

Adverse Effects

• Common: headache, flushing, dyspepsia, nasal congestion, dizziness, back pain
• Sildenafil/vardenafil: blue-green tinting of vision (PDE6 inhibition in retina)
• Tadalafil: back pain and myalgia (PDE11 inhibition in muscle)

Key Contraindications

• Nitrates (absolute): combined use causes severe hypotension via cGMP accumulation - absolutely contraindicated
• Alpha-blockers: risk of orthostatic hypotension - use with caution, stagger dosing
• Severe hepatic impairment (metabolized by CYP3A4)
• Recent MI/stroke (relative - assess cardiovascular risk first)

Second-Line Treatments

A. Intraurethral Alprostadil (MUSE)

• Prostaglandin E1 suppository inserted into the urethra
• Starting dose: 125-250 mcg, titrate up to 500-1000 mcg
• Works locally on corpora cavernosa via cAMP-mediated smooth muscle relaxation
• Side effects: urethral burning, hypotension, dizziness

B. Intracavernosal Injections (ICI)

• Self-injected into the cavernosal space with a 27-30 gauge needle
• Agents used:
  • Alprostadil (PGE1) alone - first choice for monotherapy
  • "Trimix" combination: alprostadil + papaverine + phentolamine - for PDE5 non-responders
• Efficacy: high (~80-90%)
• Side effects:
  • Pain at injection site
  • Cavernosal fibrosis (resolves after stopping)
  • Priapism (prolonged erection >4 hours) - requires urgent treatment
  • Fibrosis suggesting early Peyronie disease → stop injections
• Novel: single intracavernosal botulinum neurotoxin injection improves ED in ~40-50% of patients with tunica fibrosis

C. Vacuum Erection Devices (VED)

• Mechanical pump creates negative pressure around the penis → blood drawn into corpora cavernosa
• A constriction ring is placed at base to maintain erection
• Effective, non-pharmacological, safe
• Good option for: elderly patients, anticoagulated patients, those with contraindications to drugs
• Drawback: perceived as unnatural by some couples; cold/numb erection

Third-Line Treatment: Penile Prosthesis

• Fail or cannot tolerate all pharmacological and device-based options
• Prefer a permanent solution

Types:

Complications:

• Intraoperative: corporal perforation, urethral/bladder/bowel injury
• Postoperative: pain, infection, hematoma
• Long-term: mechanical failure (inflatable), erosion
• With proper patient/partner selection: excellent long-term satisfaction (both partners)

Special Situations

Post-Radical Prostatectomy ED

• Early penile rehabilitation with PDE5 inhibitors (nightly low-dose sildenafil) contributes to nerve recovery and erectile function restoration

Hypogonadism + ED

• Testosterone alone improves libido but not always erection
• Adding testosterone to sildenafil in partial PDE5 responders does not further improve ED
• Testosterone is indicated when serum T < 275 ng/dL with symptoms

Neurogenic ED (spinal cord injury, MS, diabetes)

• PDE5 inhibitors effective but with lower response rates
• ICI often preferred for complete spinal injury
• Viberect (vibratory device) - useful for spinal cord injury patients to promote ejaculation

2025 EAU Guidelines Update (PMID 40340108)

• Personalised treatment tailored to invasiveness, tolerability, effectiveness, and patient expectations
• Full counseling about all available modalities
• Decision-making should incorporate the patient's and partner's goals
• Concomitant ED + Peyronie disease → penile prosthesis implantation preferred